drugset / Trial / NCT04579679
Open-Label Surufatinib in European Patients With NET
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
Timeline
- Start
- 2021-08-13
- Primary completion
- 2024-09-06
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | Oral |